{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:12:20Z","timestamp":1772554340159,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u0130n\u00f6n\u00fc University Scientific Research Projects Unit","award":["TSA-2026-4656"],"award-info":[{"award-number":["TSA-2026-4656"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and\/or safety of FDM vs. IS in patients with IDA. The primary efficacy outcome was the change in hemoglobin (Hb) levels at week 4, and the safety outcome was serious or severe hypersensitivity reactions, as defined by a standardized set of Medical Dictionary for Regulatory Activities (MedDRA) terms. Inverse-variance random effects models were used for meta-analyses. Results: Five RCTs were included: two in general IDA (n = 1994), two in non-dialysis chronic kidney disease (n = 1542), and one in hemodialysis patients (n = 344). The evidence was very uncertain about the effect of FDM vs. IS for Hb change at week 4 (mean difference [MD] 0.09 g\/dL, 95% CI \u22120.33 to 0.52; I2 = 84%, very low CoE), serious or severe hypersensitivity reactions (MedDRA A + B + C + D, relative risk [RR] 0.83, 95% CI 0.25 to 2.68; I2 = 0%, very low CoE), Hb change at week 8 (MD 0.04 g\/dL, 95% CI \u22120.08 to 0.15; I2 = 0%, very low CoE), Hb increase of \u22652 g\/dL at week 4 (RR 1.16, 95% CI 0.97 to 1.38; I2 = 70%, very low CoE), and anaphylactic reactions (MedDRA A, RR 0.38, 95% CI 0.08 to 1.72; I2 = 0%, very low CoE). Conclusions: We found that FDM vs. IS had little to no effect on outcomes for the treatment of IDA.<\/jats:p>","DOI":"10.3390\/jcm15051919","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:48:56Z","timestamp":1772542136000},"page":"1919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-5234","authenticated-orcid":false,"given":"Lokman H.","family":"Tanriverdi","sequence":"first","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, \u0130n\u00f6n\u00fc University, Malatya 44100, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-0119","authenticated-orcid":false,"given":"Ahmet","family":"Sarici","sequence":"additional","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, \u0130n\u00f6n\u00fc University, Malatya 44100, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feyzullah","family":"Aksan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":false,"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"},{"name":"Unidad de Revisiones Sistem\u00e1ticas y Meta-An\u00e1lisis (URSIGET), Vicerrectorado de Investigaci\u00f3n, Universidad San Ignacio de Loyola (USIL), Lima 15024, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A systematic analysis of global anemia burden from 1990 to 2010","volume":"123","author":"Kassebaum","year":"2014","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/S2352-3026(23)00160-6","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990\u20132021: Findings from the Global Burden of Disease Study 2021","volume":"10","author":"Collaborators","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tolkien, Z., Stecher, L., Mander, A.P., Pereira, D.I., and Powell, J.J. (2015). Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117383"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"48","article-title":"Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia: Data from three non-interventional studies","volume":"156","author":"Steinmetz","year":"2014","journal-title":"MMW-Fortschritte Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/trf.15587","article-title":"The safety and efficacy of ferumoxytol in the treatment of iron deficiency: A systematic review and meta-analysis","volume":"59","author":"Abdulrehman","year":"2019","journal-title":"Transfusion"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: Administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000076401","article-title":"Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products","volume":"96","author":"Charytan","year":"2004","journal-title":"Nephron Clin. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1523-1755.2004.00872.x","article-title":"Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens","volume":"66","author":"Aronoff","year":"2004","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/ajkd.2001.28587","article-title":"Intravenous iron sucrose: Establishing a safe dose","volume":"38","author":"Chandler","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5581\/1516-8484.20110119","article-title":"Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia","volume":"33","author":"Cancado","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_12","first-page":"9","article-title":"Use of intravenous iron supplementation in chronic kidney disease: An update","volume":"7","author":"Macdougall","year":"2013","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/ajg.2013.335","article-title":"A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)","volume":"108","author":"Reinisch","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/vox.12475","article-title":"Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: A randomized controlled pilot study","volume":"112","author":"Holm","year":"2017","journal-title":"Vox Sang."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Steinheiser","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/hematology.2023000495","article-title":"IV iron formulations and use in adults","volume":"2023","author":"Auerbach","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.26124","article-title":"Intravenous ferric derisomaltose for the treatment of iron deficiency anemia","volume":"96","author":"Auerbach","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107248","DOI":"10.1016\/j.ijantimicag.2024.107248","article-title":"Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants","volume":"64","author":"Hernandez","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12185-022-03401-0","article-title":"Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: A randomized, open-label, active-controlled, noninferiority study","volume":"116","author":"Kawabata","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.23876\/j.krcp.20.120","article-title":"The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: A randomized controlled pilot study","volume":"40","author":"Kassianides","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4314\/ahs.v23i3.25","article-title":"Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: A meta-analysis of randomized controlled trials","volume":"23","author":"Shi","year":"2023","journal-title":"Afr. Health Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","article-title":"A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose","volume":"45","author":"Kennedy","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1007\/s12325-022-02242-x","article-title":"A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose","volume":"39","author":"Pollock","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imj.16184","article-title":"Intravenous iron: An update","volume":"54","author":"Lucas","year":"2024","journal-title":"Intern. Med. J."},{"key":"ref_34","first-page":"119","article-title":"Efficacy, Safety, and Tolerability of Ferric Carboxymaltose and Iron Sucrose in Iron-Deficiency Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"42","year":"2025","journal-title":"Turk. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2169\/internalmedicine.51.7450","article-title":"Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide","volume":"51","author":"Yamamoto","year":"2012","journal-title":"Intern. Med."},{"key":"ref_36","first-page":"1675654","article-title":"A Case of an Insufficiency Fracture of the Medial Proximal Tibia Secondary to Osteomalacia Associated with Long-Term Saccharated Ferric Oxide Administration","volume":"2017","author":"Ishimaru","year":"2017","journal-title":"Case Rep. Orthop."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e8147","DOI":"10.1097\/MD.0000000000008147","article-title":"A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report","volume":"96","author":"Nomoto","year":"2017","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports","volume":"37","author":"Vilaca","year":"2022","journal-title":"J. Bone Miner. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1919\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:33:30Z","timestamp":1772544810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15051919"],"URL":"https:\/\/doi.org\/10.3390\/jcm15051919","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}